– If Authorized in Europe, ADCETRIS in
Combination with AVD (Adriamycin, Vinblastine and Dacarbazine) Will Be
the First New Treatment Regimen Available for Adult Patients with
Previously Untreated CD30+ Stage IV Hodgkin Lymphoma in Decades –
– Opinion Based on Positive Phase 3 ECHELON-1 Study Results, Which
Demonstrated ADCETRIS Combination Improved Outcomes and Reduced the Need
for Additional Treatment in Adult Patients Versus ABVD (Adriamycin,
Bleomycin, Vinblastine and Dacarbazine), a Current Standard of Care –
CAMBRIDGE, Mass. & OSAKA, Japan-Monday 17 December 2018 [ AETOS Wire ]
(BUSINESS WIRE) -- Takeda Pharmaceutical Company Limited (TSE: 4502) today announced
that the European Medicines Agency’s (EMA) Committee for Medicinal
Products for Human Use (CHMP) adopted a positive opinion for the
extension of the marketing authorization of ADCETRIS (brentuximab
vedotin) and recommended its approval in combination with AVD in adult
patients with previously untreated CD30+ Stage IV Hodgkin lymphoma.
ADCETRIS is an antibody-drug conjugate (ADC) directed at CD30, a
defining marker of Hodgkin lymphoma. ADCETRIS is currently not approved
as a therapy for previously untreated Hodgkin lymphoma in Europe.
“For
a large number of previously untreated Hodgkin lymphoma patients
diagnosed with Stage IV disease, progression will occur with current
treatments, highlighting a true unmet need in this population,” said
Anna Sureda, M.D., Ph.D., Head of the Hematology Department and
Hematopoietic Stem Cell Transplant Programme, Institut Català
d'Oncologia - Hospital Duran i Reynals. “In the ECHELON-1 clinical
trial, ADCETRIS in combination with AVD reduced the risk of progression,
death or need for subsequent anticancer therapy in patients with Stage
IV disease by 29 percent versus ABVD, a standard of care. If approved in
this indication, ADCETRIS may offer an important novel treatment option
for previously untreated patients with Stage IV Hodgkin lymphoma in
Europe.”
“Today’s
positive CHMP opinion represents a significant step forward for the
European Hodgkin lymphoma community,” said Jesús Gómez-Navarro, M.D.,
Vice President, Head of Oncology Clinical Research and Development,
Takeda. “The results of the ECHELON-1 trial demonstrated a statistically
significant improvement in modified progression-free survival of in
patients who received ADCETRIS in combination with AVD compared to the
control arm. In addition to demonstrating a safety profile that was
generally consistent with that known for the single-agent components of
the regimen, in the ADCETRIS containing arm, 35 percent fewer patients
with Stage IV disease received subsequent salvage chemotherapy or
high-dose chemotherapy and transplant. We look forward to the European
Commission’s review of this CHMP positive opinion and hope to offer
ADCETRIS as a treatment option to appropriate European Hodgkin lymphoma
patients in the future.”
The
submission for ADCETRIS will now be reviewed by the European Commission
(EC), which has the authority to approve medicines for use in the
28-member states of the European Union (EU). Decisions by the EC are
also applicable in Norway, Liechtenstein and Iceland.
The
positive CHMP opinion is based on the results of the Phase 3 ECHELON-1
study designed to compare ADCETRIS plus AVD to ABVD as a therapy in
adult patients with previously untreated Hodgkin lymphoma. The trial
achieved its primary endpoint resulting in a statistically significant
improvement in modified progression-free survival (PFS) versus the
control arm (HR 0.77; p-value=0.035). Key subgroup analyses, such as
modified PFS by disease stage, showed a larger effect in patients with
Stage IV Hodgkin lymphoma in the ADCETRIS plus AVD arm versus the
control arm (HR 0.71; p-value = 0.023). This corresponds to a 29 percent
reduction in the risk of progression, death or need for additional
anticancer therapy for Stage IV patients.
About the ECHELON-1 Trial
The
randomized, open-label, two-arm, multi-center Phase 3 ECHELON-1 trial
achieved its primary endpoint with the combination of ADCETRIS+AVD
resulting in a statistically significant improvement in modified
progression-free survival (PFS) versus the control arm of ABVD as
assessed by an Independent Review Facility (IRF) (HR 0.77;
p-value=0.035). This corresponds to a 23 percent reduction in the risk
of progression, death or need for additional anticancer therapy.
- All secondary endpoints trended in favor of the ADCETRIS+AVD arm, including interim analysis of overall survival (OS; HR 0.72; p-value=0.19).
- In the ADCETRIS+AVD arm, 33 percent fewer patients received subsequent salvage chemotherapy or high-dose chemotherapy and transplant.
- The safety profile of ADCETRIS+AVD in the ECHELON-1 trial was generally consistent with that known for the single-agent components of the regimen.
- The most common clinically relevant adverse events of any grade that occurred in at least 15 percent of patients in the ADCETRIS+AVD and ABVD arms were: neutropenia, constipation, vomiting, fatigue, peripheral sensory neuropathy, diarrhea, pyrexia, peripheral neuropathy, abdominal pain and stomatitis. In both the ADCETRIS+AVD and ABVD arms, the most common Grade 3 or 4 events were neutropenia, febrile neutropenia and neutrophil count decrease.
About Hodgkin Lymphoma
Lymphoma
is a general term for a group of cancers that originate in the
lymphatic system. There are two major categories of lymphoma: Hodgkin
lymphoma and non-Hodgkin lymphoma. Hodgkin lymphoma is distinguished
from other types of lymphoma by the presence of one characteristic type
of cell, known as the Reed-Sternberg cell. The Reed-Sternberg cell
expresses CD30.
According
to the Lymphoma Coalition, approximately 67,000 people worldwide are
diagnosed with Hodgkin lymphoma each year and more than 25,000 people
die each year from this cancer.
Up
to 30 percent of previously untreated Hodgkin lymphoma patients
progress following their first therapy depending on the stage of the
disease. Only 50 percent of patients with relapsed or refractory Hodgkin
lymphoma achieve long-term remission with high-dose chemotherapy and an
autologous stem cell transplant (ASCT), a historically used treatment
regimen, highlighting the need for successful treatments for previously
untreated patients.
About ADCETRIS
ADCETRIS
is an antibody-drug conjugate (ADC) comprising an anti-CD30 monoclonal
antibody attached by a protease-cleavable linker to a microtubule
disrupting agent, monomethyl auristatin E (MMAE), utilizing Seattle
Genetics’ proprietary technology. The ADC employs a linker system that
is designed to be stable in the bloodstream but to release MMAE upon
internalization into CD30-positive tumor cells.
ADCETRIS
injection for intravenous infusion has received FDA approval for six
indications in adult patients with: (1) previously untreated systemic
anaplastic large cell lymphoma (sALCL) or other CD30-expressing
peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell
lymphoma and PTCL not otherwise specified, in combination with
cyclophosphamide, doxorubicin, and prednisone, (2) previously untreated
Stage III or IV classical Hodgkin lymphoma (cHL), in combination with
doxorubicin, vinblastine, and dacarbazine, (3) cHL at high risk of
relapse or progression as post-autologous hematopoietic stem cell
transplantation (auto-HSCT) consolidation, (4) cHL after failure of
auto-HSCT or failure of at least two prior multi-agent chemotherapy
regimens in patients who are not auto-HSCT candidates, (5) sALCL after
failure of at least one prior multi-agent chemotherapy regimen, and (6)
primary cutaneous anaplastic large cell lymphoma (pcALCL) or
CD30-expressing mycosis fungoides (MF) who have received prior systemic
therapy.
Health
Canada granted ADCETRIS approval with conditions for relapsed or
refractory Hodgkin lymphoma and sALCL in 2013, and non-conditional
approval for post-autologous stem cell transplant (ASCT) consolidation
treatment of Hodgkin lymphoma patients at increased risk of relapse or
progression.
ADCETRIS
received conditional marketing authorization from the European
Commission in October 2012. The approved indications in Europe are: (1)
for the treatment of adult patients with relapsed or refractory
CD30-positive Hodgkin lymphoma following ASCT, or following at least two
prior therapies when ASCT or multi-agent chemotherapy is not a
treatment option, (2) the treatment of adult patients with relapsed or
refractory sALCL, (3) for the treatment of adult patients with
CD30-positive Hodgkin lymphoma at increased risk of relapse or
progression following ASCT, and (4) for the treatment of adult patients
with CD30-positive cutaneous T-cell lymphoma (CTCL) after at least one
prior systemic therapy.
ADCETRIS
has received marketing authorization by regulatory authorities in more
than 70 countries for relapsed or refractory Hodgkin lymphoma and sALCL.
See important safety information below.
ADCETRIS
is being evaluated broadly in more than 70 clinical trials, including a
Phase 3 study in first-line Hodgkin lymphoma (ECHELON-1) and another
Phase 3 study in first-line CD30-positive peripheral T-cell lymphomas
(ECHELON-2), as well as trials in many additional types of CD30-positive
malignancies.
Seattle
Genetics and Takeda are jointly developing ADCETRIS. Under the terms of
the collaboration agreement, Seattle Genetics has U.S. and Canadian
commercialization rights and Takeda has rights to commercialize ADCETRIS
in the rest of the world. Seattle Genetics and Takeda are funding joint
development costs for ADCETRIS on a 50:50 basis, except in Japan where
Takeda is solely responsible for development costs.
ADCETRIS (brentuximab vedotin) Important Safety Information (European Union)
Please refer to Summary of Product Characteristics (SmPC) before prescribing.
CONTRAINDICATIONS
ADCETRIS
is contraindicated for patients with hypersensitivity to brentuximab
vedotin and its excipients. In addition, combined use of ADCETRIS with
bleomycin causes pulmonary toxicity.
SPECIAL WARNINGS & PRECAUTIONS
Progressive multifocal leukoencephalopathy (PML): John
Cunningham virus (JCV) reactivation resulting in progressive multifocal
leukoencephalopathy (PML) and death can occur in patients treated with
ADCETRIS. PML has been reported in patients who received ADCETRIS after
receiving multiple prior chemotherapy regimens. PML is a rare
demyelinating disease of the central nervous system that results from
reactivation of latent JCV and is often fatal.
Closely
monitor patients for new or worsening neurological, cognitive, or
behavioral signs or symptoms, which may be suggestive of PML. Suggested
evaluation of PML includes neurology consultation, gadolinium-enhanced
magnetic resonance imaging of the brain, and cerebrospinal fluid
analysis for JCV DNA by polymerase chain reaction or a brain biopsy with
evidence of JCV. A negative JCV PCR does not exclude PML. Additional
follow up and evaluation may be warranted if no alternative diagnosis
can be established Hold dosing for any suspected case of PML and
permanently discontinue ADCETRIS if a diagnosis of PML is confirmed.
Be alert to PML symptoms that the patient may not notice (e.g., cognitive, neurological, or psychiatric symptoms).
Pancreatitis: Acute
pancreatitis has been observed in patients treated with ADCETRIS. Fatal
outcomes have been reported. Closely monitor patients for new or
worsening abdominal pain, which may be suggestive of acute pancreatitis.
Patient evaluation may include physical examination, laboratory
evaluation for serum amylase and serum lipase, and abdominal imaging,
such as ultrasound and other appropriate diagnostic measures. Hold
ADCETRIS for any suspected case of acute pancreatitis. ADCETRIS should
be discontinued if a diagnosis of acute pancreatitis is confirmed.
Pulmonary Toxicity: Cases
of pulmonary toxicity, some with fatal outcomes, including pneumonitis,
interstitial lung disease, and acute respiratory distress syndrome
(ARDS), have been reported in patients receiving ADCETRIS. Although a
causal association with ADCETRIS has not been established, the risk of
pulmonary toxicity cannot be ruled out. Promptly evaluate and treat new
or worsening pulmonary symptoms appropriately. Consider holding dosing
during evaluation and until symptomatic improvement.
Serious infections and opportunistic infections: Serious
infections such as pneumonia, staphylococcal bacteremia, sepsis/septic
shock (including fatal outcomes), and herpes zoster, and opportunistic
infections such as Pneumocystis jiroveci pneumonia and oral
candidiasis have been reported in patients treated with ADCETRIS.
Carefully monitor patients during treatment for emergence of possible
serious and opportunistic infections.
Infusion-related reactions (IRR): Immediate
and delayed IRR, as well as anaphylaxis, have occurred with ADCETRIS.
Carefully monitor patients during and after an infusion. If anaphylaxis
occurs, immediately and permanently discontinue administration of
ADCETRIS Appropriate medical therapy should be administered. If an IRR
occurs, interrupt the infusion and institute appropriate medical
management. The infusion may be restarted at a slower rate after symptom
resolution. Patients who have experienced a prior IRR should be
premedicated for subsequent infusions. IRRs are more frequent and more
severe in patients with antibodies to ADCETRIS.
Tumor lysis syndrome (TLS): TLS
has been reported with ADCETRIS. Patients with rapidly proliferating
tumor and high tumor burden are at risk of TLS. Monitor these patients
closely and managed according to best medical practice.
Peripheral neuropathy (PN): ADCETRIS
treatment may cause PN, both sensory and motor. ADCETRIS-induced PN is
typically cumulative and reversible in most cases. Monitor patients for
symptoms of PN, such as hypoesthesia, hyperesthesia, paresthesia,
discomfort, a burning sensation, neuropathic pain, or weakness. Patients
experiencing new or worsening PN may require a delay and a dose
reduction or discontinuation of ADCETRIS.
Hematological toxicities: Grade
3 or Grade 4 anemia, thrombocytopenia, and prolonged (equal to or
greater than one week) Grade 3 or Grade 4 neutropenia can occur with
ADCETRIS. Monitor complete blood counts prior to administration of each
dose.
Febrile neutropenia: Febrile
neutropenia has been reported. Closely monitor patients for fever and
manage according to best medical practice if febrile neutropenia
develops.
Stevens-Johnson syndrome (SJS): SJS
and toxic epidermal necrolysis (TEN) have been reported with ADCETRIS.
Fatal outcomes have been reported. Discontinue treatment with ADCETRIS
if SJS or TEN occurs and administer appropriate medical therapy.
Gastrointestinal (GI) Complications: GI
complications, some with fatal outcomes, including intestinal
obstruction, ileus, enterocolitis, neutropenic colitis, erosion, ulcer,
perforation and haemorraghe, have been reported. Promptly evaluate and
treat patients if new or worsening GI symptoms occur.
Hepatotoxicity: Elevations
in alanine aminotransferase (ALT) and aspartate aminotransferase (AST)
have been reported. Serious cases of hepatotoxicity, including fatal
outcomes, have also occurred. Test liver function prior to treatment
initiation and routinely monitor patients receiving ADCETRIS for liver
elevations. Patients experiencing hepatotoxicity may require a delay,
dose modification, or discontinuation of ADCETRIS.
Hyperglycemia: Hyperglycemia
has been reported during trials in patients with an elevated body mass
index (BMI) with or without a history of diabetes mellitus. Closely
monitor serum glucose for patients who experiences an event of
hyperglycemia. Administer anti-diabetic treatment as appropriate.
Renal and Hepatic Impairment: There
is limited experience in patients with renal and hepatic impairment.
Available data indicate that MMAE clearance might be affected by severe
renal impairment, hepatic impairment, and by low serum albumin
concentrations.
CD30+ CTCL: The
size of the treatment effect in CD30 + CTCL subtypes other than mycosis
fungoides (MF) and primary cutaneous anaplastic large cell lymphoma
(pcALCL) is not clear due to lack of high level evidence. In two single
arm phase II studies of ADCETRIS, disease activity has been shown in the
subtypes Sézary syndrome (SS), lymphomatoid papulosis (LyP) and mixed
CTCL histology. These data suggest that efficacy and safety can be
extrapolated to other CTCL CD30+ subtypes. Carefully consider the
benefit-risk per patient and use caution in other CD30+ CTCL patient
types.
Sodium content in excipients: ADCETRIS
contains a maximum of 2.1 mmol (or 47 mg) of sodium per dose. Take this
into consideration for patients on a controlled sodium diet.
INTERACTIONS
Patients
who are receiving a strong CYP3A4 and P-gp inhibitor, concomitantly
with ADCETRIS may have an increased risk of neutropenia and should be
closely monitored. Co-administration of ADCETRIS with a CYP3A4 inducer
did not alter the plasma exposure of ADCETRIS but it appeared to reduce
plasma concentrations of MMAE metabolites that could be assayed.
ADCETRIS is not expected to alter the exposure to drugs that are
metabolized by CYP3A4 enzymes.
PREGNANCY: Advise
women of childbearing potential to use two methods of effective
contraception during treatment with ADCETRIS and until 6 months after
treatment. There are no data from the use of ADCETRIS in pregnant women,
although studies in animals have shown reproductive toxicity. Do not
use ADCETRIS during pregnancy unless the benefit to the mother outweighs
the potential risks to the fetus.
LACTATION (breast-feeding): There
are no data as to whether ADCETRIS or its metabolites are excreted in
human milk, therefore a risk to the newborn/infant cannot be excluded.
With the potential risk, a decision should be made whether to
discontinue breast-feeding or discontinue/abstain from therapy with
ADCETRIS.
FERTILITY: In
nonclinical studies, ADCETRIS treatment has resulted in testicular
toxicity, and may alter male fertility. Advise men being treated with
ADCETRIS not to father a child during treatment and for up to 6 months
following the last dose.
Effects on ability to drive and use machines: ADCETRIS may have a minor influence on the ability to drive and use machines.
UNDESIRABLE EFFECTS
The
most frequent adverse reactions (≥10%) were infections, peripheral
sensory neuropathy, nausea, fatigue, diarrhoea, pyrexia, upper
respiratory tract infection, neutropenia, rash, cough, vomiting,
arthralgia, peripheral motor neuropathy, infusion-related reactions,
pruritus, constipation, dyspnoea, weight decreased, myalgia and
abdominal pain.
Serious
adverse drug reactions were: pneumonia, acute respiratory distress
syndrome, headache, neutropenia, thrombocytopenia, constipation,
diarrhea, vomiting, nausea, pyrexia, peripheral motor neuropathy,
peripheral sensory neuropathy, hyperglycemia, demyelinating
polyneuropathy, tumor lysis syndrome, and Stevens-Johnson syndrome.
Serious adverse drug reactions occurred in 12% of patients. The
frequency of unique serious adverse drug reactions was ≤1%.
ADCETRIS (brentuximab vedotin) Important Safety Information (U.S.)
BOXED WARNING: PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML):
JC virus infection resulting in PML and death can occur in ADCETRIS-treated patients.
Contraindication
ADCETRIS concomitant with bleomycin due to pulmonary toxicity (e.g., interstitial infiltration and/or inflammation).
Warnings and Precautions
- Peripheral neuropathy (PN): ADCETRIS causes PN that is predominantly sensory. Cases of motor PN have also been reported. ADCETRIS-induced PN is cumulative. Monitor for symptoms such as hypoesthesia, hyperesthesia, paresthesia, discomfort, a burning sensation, neuropathic pain, or weakness. Institute dose modifications accordingly.
- Anaphylaxis and infusion reactions: Infusion-related reactions (IRR), including anaphylaxis, have occurred with ADCETRIS. Monitor patients during infusion. If an IRR occurs, interrupt the infusion and institute appropriate medical management. If anaphylaxis occurs, immediately and permanently discontinue the infusion and administer appropriate medical therapy. Premedicate patients with a prior IRR before subsequent infusions. Premedication may include acetaminophen, an antihistamine, and a corticosteroid.
- Hematologic toxicities: Fatal and serious cases of febrile neutropenia have been reported with ADCETRIS. Prolonged (≥1 week) severe neutropenia and Grade 3 or 4 thrombocytopenia or anemia can occur with ADCETRIS. Start primary prophylaxis with G-CSF beginning with Cycle 1 for patients who receive ADCETRIS in combination with chemotherapy for previously untreated Stage III or IV classical HL or previously untreated PTCL. Monitor complete blood counts prior to each ADCETRIS dose. Monitor more frequently for patients with Grade 3 or 4 neutropenia. Monitor patients for fever. If Grade 3 or 4 neutropenia develops, consider dose delays, reductions, discontinuation, or G-CSF prophylaxis with subsequent ADCETRIS doses.
- Serious infections and opportunistic infections: Infections such as pneumonia, bacteremia, and sepsis or septic shock (including fatal outcomes) have been reported in ADCETRIS-treated patients. Closely monitor patients during treatment for bacterial, fungal, or viral infections.
- Tumor lysis syndrome: Closely monitor patients with rapidly proliferating tumor and high tumor burden.
- Increased toxicity in the presence of severe renal impairment: The frequency of ≥Grade 3 adverse reactions and deaths was greater in patients with severe renal impairment compared to patients with normal renal function. Avoid use in patients with severe renal impairment.
- Increased toxicity in the presence of moderate or severe hepatic impairment: The frequency of ≥Grade 3 adverse reactions and deaths was greater in patients with moderate or severe hepatic impairment compared to patients with normal hepatic function. Avoid use in patients with moderate or severe hepatic impairment.
- Hepatotoxicity: Fatal and serious cases have occurred in ADCETRIS-treated patients. Cases were consistent with hepatocellular injury, including elevations of transaminases and/or bilirubin, and occurred after the first ADCETRIS dose or rechallenge. Preexisting liver disease, elevated baseline liver enzymes, and concomitant medications may increase the risk. Monitor liver enzymes and bilirubin. Patients with new, worsening, or recurrent hepatotoxicity may require a delay, change in dose, or discontinuation of ADCETRIS.
- PML: Fatal cases of JC virus infection resulting in PML and death have been reported in ADCETRIS-treated patients. First onset of symptoms occurred at various times from initiation of ADCETRIS therapy, with some cases occurring within 3 months of initial exposure. Other possible contributory factors other than ADCETRIS include prior therapies and underlying disease that may cause immunosuppression. Consider PML diagnosis in patients with new-onset signs and symptoms of central nervous system abnormalities. Hold ADCETRIS if PML is suspected and discontinue ADCETRIS if PML is confirmed.
- Pulmonary toxicity: Fatal and serious events of noninfectious pulmonary toxicity including pneumonitis, interstitial lung disease, and acute respiratory distress syndrome have been reported. Monitor patients for signs and symptoms, including cough and dyspnea. In the event of new or worsening pulmonary symptoms, hold ADCETRIS dosing during evaluation and until symptomatic improvement.
- Serious dermatologic reactions: Fatal and serious cases of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported with ADCETRIS. If SJS or TEN occurs, discontinue ADCETRIS and administer appropriate medical therapy.
- Gastrointestinal (GI) complications: Fatal and serious cases of acute pancreatitis have been reported. Other fatal and serious GI complications include perforation, hemorrhage, erosion, ulcer, intestinal obstruction, enterocolitis, neutropenic colitis, and ileus. Lymphoma with preexisting GI involvement may increase the risk of perforation. In the event of new or worsening GI symptoms, perform a prompt diagnostic evaluation and treat appropriately.
- Embryo-fetal toxicity: Based on the mechanism of action and animal studies, ADCETRIS can cause fetal harm. Advise females of reproductive potential of the potential risk to the fetus, and to avoid pregnancy during ADCETRIS treatment and for at least 6 months after the final dose of ADCETRIS.
Most Common (≥20% in any study) Adverse Reactions: Peripheral
neuropathy, fatigue, nausea, diarrhea, neutropenia, upper respiratory
tract infection, pyrexia, constipation, vomiting, alopecia, decreased
weight, abdominal pain, anemia, stomatitis, lymphopenia and mucositis.
Drug Interactions
Concomitant
use of strong CYP3A4 inhibitors or inducers has the potential to affect
the exposure to monomethyl auristatin E (MMAE).
Use in Specific Populations
Moderate or severe hepatic impairment or severe renal impairment: MMAE exposure and adverse reactions are increased. Avoid use.
Advise
males with female sexual partners of reproductive potential to use
effective contraception during ADCETRIS treatment and for at least 6
months after the final dose of ADCETRIS.
Advise patients to report pregnancy immediately and avoid breastfeeding while receiving ADCETRIS.
For
additional Important Safety Information, including BOXED WARNING,
please see the full Prescribing Information for ADCETRIS at www.seattlegenetics.com or http://www.ADCETRIS.com.
About Takeda Pharmaceutical Company
Takeda Pharmaceutical Company Limited (TSE: 4502)
is a global, research and development-driven pharmaceutical company
committed to bringing better health and a brighter future to patients by
translating science into life-changing medicines. Takeda focuses its
R&D efforts on oncology, gastroenterology and neuroscience
therapeutic areas plus vaccines. Takeda conducts R&D both internally
and with partners to stay at the leading edge of innovation. Innovative
products, especially in oncology and gastroenterology, as well as
Takeda’s presence in emerging markets, are currently fueling the growth
of Takeda. Approximately 30,000 Takeda employees are committed to
improving quality of life for patients, working with Takeda’s partners
in health care in more than 70 countries.
For more information, visit https://www.takeda.com/newsroom/.
Additional information about Takeda is available through its corporate website, www.takeda.com,
and additional information about Takeda Oncology, the brand for the
global oncology business unit of Takeda Pharmaceutical Company Limited,
is available through its website, www.takedaoncology.com.
Contacts
Japanese Media
Kazumi Kobayashi
kazumi.kobayashi@takeda.com
+81 (0) 3-3278-2095
Media outside Japan
Sara Noonan
sara.noonan@takeda.com
+1-617-551-3683
No comments:
Post a Comment